文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Pharmacogenetics in Primary Headache Disorders.

作者信息

Belyaeva Irina I, Subbotina Anna G, Eremenko Ivan I, Tarasov Vadim V, Chubarev Vladimir N, Schiöth Helgi B, Mwinyi Jessica

机构信息

Department of Surgical Sciences, Functional Pharmacology and Neuroscience, University of Uppsala, Uppsala, Sweden.

Department of Pharmacology, Institute of Pharmacy, I. M. Sechenov First Moscow State Medical University, Moscow, Russia.

出版信息

Front Pharmacol. 2022 Feb 10;12:820214. doi: 10.3389/fphar.2021.820214. eCollection 2021.


DOI:10.3389/fphar.2021.820214
PMID:35222013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8866828/
Abstract

Primary headache disorders, such as migraine, tension-type headache (TTH), and cluster headache, belong to the most common neurological disorders affecting a high percentage of people worldwide. Headache induces a high burden for the affected individuals on the personal level, with a strong impact on life quality, daily life management, and causes immense costs for the healthcare systems. Although a relatively broad spectrum of different pharmacological classes for the treatment of headache disorders are available, treatment effectiveness is often limited by high variances in therapy responses. Genetic variants can influence the individual treatment success by influencing pharmacokinetics or pharmacodynamics of the therapeutic as investigated in the research field of pharmacogenetics. This review summarizes the current knowledge on important primary headache disorders, including migraine, TTH, and cluster headache. We also summarize current acute and preventive treatment options for the three headache disorders based on drug classes and compounds taking important therapy guidelines into consideration. Importantly, the work summarizes and discusses the role of genetic polymorphisms regarding their impact on metabolism safety and the effect of therapeutics that are used to treat migraine, cluster headache, and TTH exploring drug classes such as nonsteroidal anti-inflammatory drugs, triptans, antidepressants, anticonvulsants, calcium channel blockers, drugs with effect on the renin-angiotensin system, and novel headache therapeutics such as ditans, anti-calcitonin-gene-related peptide antibodies, and gepants. Genetic variants in important phase I-, II-, and III-associated genes such as cytochrome P450 genes, UGT genes, and different transporter genes are scrutinized as well as variants in genes important for pharmacodynamics and several functions outside the pharmacokinetic and pharmacodynamic spectrum. Finally, the article evaluates the potential and limitations of pharmacogenetic approaches for individual therapy adjustments in headache disorders.

摘要

相似文献

[1]
Pharmacogenetics in Primary Headache Disorders.

Front Pharmacol. 2022-2-10

[2]
Pharmacokinetics and pharmacodynamics of new acute treatments for migraine.

Expert Opin Drug Metab Toxicol. 2019-2-12

[3]
Migraine and Tension-Type Headache.

Semin Neurol. 2018-12

[4]
Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations.

Expert Opin Drug Metab Toxicol. 2016

[5]
Sleep-related headache and its management.

Curr Treat Options Neurol. 2013-12

[6]
Galcanezumab effectiveness on comorbid cluster headache and chronic migraine: a prospective case series.

Neurol Sci. 2022-1

[7]
Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review.

Headache. 2019-7

[8]
A narrative review of the importance of pharmacokinetics and drug-drug interactions of preventive therapies in migraine management.

Headache. 2021-6

[9]
Survey on treatments for primary headaches in 13 specialized juvenile Headache Centers: The first multicenter Italian study.

Eur J Paediatr Neurol. 2017-5

[10]
Use of Nonsteroidal Anti-Inflammatory Drugs for Symptomatic Treatment of Episodic Headache.

Pain Pract. 2017-3

引用本文的文献

[1]
Cluster Headache and Migraine Shared and Unique Insights: Neurophysiological Implications, Neuroimaging, and Biomarkers: A Comprehensive Review.

J Clin Med. 2025-3-21

[2]
Managing Cluster Headache in Patients with Medical, Psychiatric, and Surgical Comorbidities.

Curr Neurol Neurosci Rep. 2024-9

[3]
Primary Dengue and Long-Term Health Status in Madeira Island, Portugal: A Retrospective Questionnaire-Based Study.

Am J Trop Med Hyg. 2024-8-7

[4]
New management strategies for primary headache disorders: Insights from P4 medicine.

Heliyon. 2023-11-14

[5]
Genetics of migraine: where are we now?

J Headache Pain. 2023-2-20

[6]
Relationship Between Changes in Cranio-Cervical Extensor Muscles and Quality of Life: A Single-Center Study of 15 Patients with Chronic Tension-Type Headache.

Med Sci Monit. 2023-2-13

[7]
Polymorphisms of the Proinflammatory Cytokine Genes Modulate the Response to NSAIDs but Not to Triptans in Migraine Attacks.

Int J Mol Sci. 2022-12-30

本文引用的文献

[1]
Effects of CYP2C19*17 Genetic Polymorphisms on the Steady-State Concentration of Diazepam in Patients With Alcohol Withdrawal Syndrome.

Hosp Pharm. 2021-10

[2]
Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments.

Br J Pharmacol. 2021-12

[3]
Drug use evaluation: A two-year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder.

Brain Behav. 2021-8

[4]
Role of CGRP pathway polymorphisms in migraine: a systematic review and impact on CGRP mAbs migraine therapy.

J Headache Pain. 2021-7-30

[5]
Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity.

Front Pharmacol. 2021-6-21

[6]
Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics.

Pharmacogenomics. 2021-6

[7]
Genetic variants related to successful migraine prophylaxis with verapamil.

Mol Genet Genomic Med. 2021-6

[8]
Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters.

Pharmaceuticals (Basel). 2021-3-1

[9]
High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis.

J Transl Med. 2021-3-31

[10]
Tension-type headache.

Nat Rev Dis Primers. 2021-3-25

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索